CD28 is a costimulatory receptor found on the surface of most T lymphocytes. Engagement of CD28 induces interleukin 2 (IL-2) production and cell proliferation when combined with an additional signal such as treatment with phorbol ester, an activator of protein kinase C. Recent studies have established that after CD28 ligation, the cytoplasmic domain of CD28 can bind to the 85-kDa subunit of phosphatidylinositol 3-kinase (PI3 kinase). There is a concomitant increase in PI3 lipid kinase activity that may be important in CD28 signaling. Despite the requirement of phorbol 12-myristate 13-acetate (PMA) for effector function, we have found, however, that treatment of Jurkat T cells with the phorbol ester PMA dramatically inhibits (i) the association of PI3 kinase with CD28, (ii) the ability of p85 PI3 kinase to be immunoprecipitated by anti-phosphotyrosine antibodies, and (iii) the induction of P13 kinase activity after stimulation of the cells with the anti-CD28 monoclonal antibody 9.3. These changes occur within minutes of PMA treatment and are persistent. In addition, we have found that wortmannin, a potent inhibitor of PI3 kinase, does not interfere with the induction of IL-2 after stimulation of Jurkat T cells with anti-CD28 monoclonal antibody and PMA. We conclude that PI3 kinase activity may not be required for CD28-dependent IL-2 production from Jurkat T cells in the presence of PMA.
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Effective T-cell activation is thought to require the triggering of two disparate signal transduction cascades. Ligation of the costimulatory receptor CD28 by anti-CD28 monoclonal antibody (mAb) can lead to interleukin 2 (IL-2) production and cellular proliferation in the presence of an additional signal provided by the phorbol ester phorbol 12-myristate 13-acetate (PMA) (1) . Signaling through the CD28 receptor remains poorly understood. Stimulation of CD28 leads to the increased phosphorylation on tyrosine of several proteins, including the intracellular domain of CD28 itself (2, 3) and the cytoplasmic tyrosine kinases Lck, Fyn, and Emt/Itk/Tsk (2, 4, 5) . Tyrosine phosphorylation of CD28 allows binding to the Src homology 2 (SH2) domains of the 85-kDa subunit of phosphatidylinositol 3-kinase (PI3 kinase), leading to a concomitant increase in P13 kinase activity (3, (6) (7) (8) (9) (10) . The 85-kDa regulatory subunit of PI3 kinase contains two SH2 domains and one SH3 domain. The lipid kinase activity is mediated by a tightly associated 110-kDa catalytic domain (11) . The phosphorylated lipid products of PI3 kinase, phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate (PIP3), are considered to be important intracellular mediators, yet their specific functions and their role in CD28-dependent signaling has yet to be established.
We previously reported that PMA treatment of Jurkat T cells or purified human peripheral T lymphocytes resulted in a striking alteration in the phosphorylation profile of CD28 and associated proteins in immune complex kinase assays (2) . Since PMA can supply the additional signal necessary for CD28-dependent IL-2 production, it may modulate the enzymatic activity or physical association of accessory signaling proteins with the CD28 cytoplasmic tail. We now report that PMA treatment of Jurkat T cells prevented the physical association of the 85-kDa subunit of P13 kinase with CD28 and inhibited the immunoprecipitation of P13 kinase by antiphosphotyrosine antibodies. Importantly, PMA treatment inhibited the induction of P13 kinase activity after stimulation of the cells with anti-CD28 mAb. These changes were both rapid and persistent. Last, we have found that wortmannin, a selective inhibitor of P13 kinase activity, did not inhibit the induction of IL-2 after stimulation of Jurkat T cells with anti-CD28 mAb and PMA. Our findings are consistent with the conclusion that P13 kinase activity may not be required for CD28 and PMA-dependent IL-2 production from Jurkat T cells.
MATERIALS AND METHODS Cells and Transfections. The T-cell leukemia cell lines
Jurkat clone J77 (gift of Kendall Smith, Cornell University, New York) and HUT 78 (American Type Culture Collection) were cultured as described (2) . Where indicated, cells were grown overnight in medium containing 1% (vol/vol) fetal calf serum. The cDNA encoding CD28 (gift of Brian Seed, Harvard Medical School) was excised from 7rH3M by digestion with Xba I and ligated into the expression vector pMH-Neo (12) (pMH-CD28). This plasmid was introduced into HUT 78 cells by electroporation (300 V, 10 msec, and 980 ,uF); transfectants were selected in G418 and screened for CD28 surface expression.
Antibodies. The anti-CD28 mAb 9.3 (Bristol-Meyers Squibb) and the anti-CD3 mAb OKT3 (American Type Culture Collection) were used. The anti-phosphotyrosine mAb 4G10 was a gift from T. Roberts (Dana-Farber Cancer Institute). Antisera against the p85 subunit of P13 kinase (Upstate Biotechnology, Lake Placid, NY), the pllO subunit of P13 kinase, and agarose-conjugated anti-phosphotyrosine mAb (Santa Cruz Biotechnology, Santa Cruz, CA) were used. 'ITo whom reprint requests should be sent at the * address.
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presence of IL-2 by their ability to support the proliferation of the IL-2-dependent murine T-cell line CTLL-20 in comparison to a standard of recombinant human IL-2.
Cell Stimulations, Immunoprecipitations, and Lipid Kinase Assays. Cells (usually 1 X 107) were resuspended in 0.5 ml of buffer A [RPMI 1640 medium supplemented with penicillin (100 units/ml), streptomycin (100 ,ug/ml), 10 mM Hepes (pH 7.2), and 2 mM glutamine] and incubated with the anti-CD28 mAb 9.3 for 15 min on ice followed by incubation at 37°C for the times indicated. The cells were washed in buffer A, resuspended in 1 ml of lysis buffer [1% Nonidet P-40 (NP-40)/ 150 mM NaCl/25 mM Hepes, pH 7.5/1 mM EDTA/2.5 mM sodium orthovanadate/protease inhibitors (soybean trypsin inhibitor at 100 ,ug/ml, leupeptin at 10 ,ug/ml, and aprotinin at 10 ,g/ml)] and incubated on ice for 15 min. Lysates were clarified by centrifugation at 14,000 x g for 10 min at 4°C. Anti-CD28 or anti-phosphotyrosine immunoprecipitates were washed three times with 1% NP-40 lysis buffer, twice in buffer B (0.5 M LiCl/100 mM Hepes, pH 7.5/2.5 mM sodium orthovanadate/protease inhibitors) and twice with buffer C (100 mM NaCl/25 mM Hepes, pH 7.5/1 mM EDTA/2.5 mM sodium orthovanadate/protease inhibitors). For experiments involving PMA treatment, control cells were treated with an equal amount of the diluent ethanol. PI3 kinase assays were performed as described (13) .
RESULTS
PMA, Although Required for CD28-Mediated IL-2 Production, Inhibits CD28-Dependent P13 Kinase Activation. While stimulation of Jurkat T cells with PMA or anti-CD28 mAb 9.3 alone was insufficient to induce IL-2 production, combined stimulation with both PMA and anti-CD28 mAb induced substantial levels of IL-2 production (Table 1 ). This synergistic effect was constant at PMA concentrations ranging from 1 to 50 ng/ml. We therefore investigated whether treatment of Jurkat T cells with comparable amounts of PMA (5 ng/ml unless otherwise indicated) altered early CD28-dependent signaling events, in particular the activation of PI3 kinase.
The 85-kDa regulatory subunit of PI3 kinase can bind, in an SH2-dependent manner, to proteins containing the consensus sequence pYM/VXM (11) . Ligation of CD28, whose intracellular domain contains a YMNM site (14) , with anti-CD28 mAb leads to the physical association of PI3 kinase (3, (6) (7) (8) (9) (10) . Anti-CD28 immunoprecipitates were prepared from NP-40 lysates of cells that had been incubated without or with anti-CD28 mAb for 5 min at 37°C. After separation by SDS/PAGE on 6-15% gradient gels, the immunoprecipitated proteins were transferred to poly(vinylidene difluoride) and probed with antisera against p85 PI3 kinase. In the absence of stimulation through CD28, no P13 kinase polypeptide was associated with the receptor (Fig. 1, lane 2) . Only the CD28 immunoprecipitates prepared from cells that had been stimulated with anti-CD28 mAb contained associated p85 P13 kinase (Fig. 1, lanes 2 and 3) . The binding of p85 P13 kinase to CD28 occurred quickly following stimulation of Jurkat T cells with soluble anti-CD28 mAb at 37°C (see Fig. 3A Left) . To confirm that this activity was CD28-dependent and not unique to Jurkat T cells, we analyzed a different human T cell line, HUT 78. The HUT 78 cells do not express cell surface CD28 by indirect immunofluorescence staining (data not shown), and p85 P13 kinase was not detected in CD28 immunoprecipitates prepared from these cells (Fig. 1, lanes 4 and 5) . HUT 78 cells were transfected with the cDNA encoding human CD28, selected in neomycin, and screened for expression of CD28 by immunofluorescence (data not shown). Two separate stable subclones, HUT 78-28.1 and HUT 78-28.2, demonstrated p85 P13 kinase association with CD28 immunoprecipitates only using lysates prepared from anti-CD28 mAb-stimulated cells (Fig. 1, lanes 6-9) . Importantly, in both Jurkat and HUT 78 cells, this induction of the association of P13 kinase with CD28 required only the ligation of CD28 with soluble anti-CD28 mAb and did not require stimulation of the cells with PMA.
We evaluated the CD28-dependent stimulation of P13 kinase activity. CD28 immunoprecipitates were prepared from NP-40 lysates of Jurkat T cells that had been incubated for 5 min at 37°C with or without anti-CD28 mAb. After rigorous washing, these immunoprecipitates were assayed for associated PI3 kinase activity. The immunoprecipitates were incubated with [y-32P]ATP and the lipid kinase substrates phosphatidylinositol and phosphatidylinositol 3,4-bisphosphate. The 32P-labeled reaction products were separated by thin layer chromatography, detected by autoradiography, and quantified by scintillation counting of the radiolabel incorporated into PIP3. There was an almost 3-fold increase in PI3 kinase activity in CD28 immunoprecipitates prepared from cells stimulated with anti-CD28 mAb ( Fig. 2A, bars 1 and 2 ). In six separate experiments, the CD28-dependent stimulation of P13 kinase ranged between 1-and 12-fold, with a mean of 4-fold (data not shown). Comparable results were obtained when anti-phosphotyrosine immunoprecipitates were assayed for CD28-dependent stimulation of P13 kinase activity (Fig. 2B) . In these experiments, a time-dependent increase in PI3 kinase activity was readily apparent within 45 sec and peaked between 5 and 10 min after stimulation (Fig. 2B) . By 30 min the PI3 kinase activity had diminished but was still detectable (2- (Fig. 2) .
Since IL-2 production requires not only anti-CD28 mAb treatment but also an additional signal such as PMA, we tested the effect of PMA treatment on PI3 kinase activity induced by anti-CD28 mAb. Surprisingly, the preincubation of Jurkat T cells with PMA at 5 ng/ml for 30 min at 37°C completely abolished the CD28-dependent stimulation of PI3 kinase activity detected in CD28 immunoprecipitates (Fig. 2B, lanes  3 and 4) . We examined the effect of temperature and the duration of the phorbol ester pretreatment on the PMAinduced abrogation of the CD28-dependent induction of P13 kinase activity. The effect of PMA was rapid. Incubation of the cells with PMA at 5 ng/ml for 5 min on ice was sufficient to inhibit almost all of the CD28-dependent stimulation of PI3 kinase activity in anti-phosphotyrosine immunoprecipitates across the entire time course of CD28 stimulation (Fig. 2B,  lanes 2, 4, 6, and 8) . The PMA-dependent inhibition of CD28-dependent P13 kinase activity was long lasting. Treatment of the cells with PMA at 5 ng/ml for 18 hr prior to harvest and stimulation with anti-CD28 mAb was sufficient to abrogate the induction of P13 kinase activity (data not shown). PMA treatment did not markedly influence PI3 kinase activity as measured in whole-cell detergent lysates, p85 PI3 kinase immunoprecipitates, or pllO PI3 kinase immunoprecipitates (data not shown). Thus, the delivery of a combination of signals sufficient to induce IL-2 production-namely, PMA with anti-CD28 mAb-did not lead to a significant increase in PI3 kinase activity.
PMA Treatment Inhibits the Physical Association of p85 P13 Kinase with CD28 as well as the Immunoprecipitation of p85 P13 Kinase by Anti-Phosphotyrosine Antibodies After Stimulation with CD28 mAb. We next examined whether PMA treatment had any effect on the ability of CD28 and P13 kinase to interact physically. CD28 immunoprecipitates were prepared from Jurkat T cells incubated without or with PMA at 5 ng/ml for 5 min on ice and then stimulated for various amounts of time with anti-CD28 mAb. The immunoprecipitates were probed for the presence of associated PI3 kinase by blotting with anti-p85 P13 kinase antisera. In the absence of PMA, there was a clear activation-dependent increase in the amount of p85 PI3 kinase present in the CD28 immunoprecipitates (Fig. 3A Left) . The time course of p85 PI3 kinase association with CD28 (Fig. 3A Left) parallels the time course of the CD28-dependent induction of PI3 kinase activity detected in anti-phosphotyrosine immunoprecipitates (Fig. 2B ) and anti-CD28 immunoprecipitates (Fig. 24 and data not  shown) . However, in CD28 immunoprecipitates prepared from PMA-treated cells, there is a marked decrease in the amount of activation-induced association of p85 PI3 kinase (Fig. 3A  Right) . PMA pretreatment also decreased the immunoprecipitation of p85 PI3 kinase by anti-phosphotyrosine antibody after anti-CD28 mAb stimulation of Jurkat T cells (Fig. 3B) and HUT 78-28.1 and HUT 78-28.2 cells (data not shown). Pretreatment of the cells with PMA for 90 min at 37°C (Fig.   3C ) or increasing the concentration of PMA to 50 ng/ml further inhibited the immunoprecipitation of p85 PI3 kinase by anti-phosphotyrosine antibody following anti-CD28 mAb stimulation (Fig. 3D) . Thus, PMA treatment appeared to prevent the physical association of PI3 kinase with CD28 after treatment of Jurkat T cells with anti-CD28 mAb. PMA also caused a marked decrease in the CD28-dependent induction of the tyrosine phosphorylation of PI3 kinase.
A Potent P13 Kinase Inhibitor, Wortmannin, Does Not Inhibit CD28-Dependent IL-2 Pioduction from Jurkat T Cells. Our finding that PMA treatment abrogated the CD28-induced association and activation of P13 kinase led us to investigate whether P13 kinase activity was required for CD28-dependent IL-2 production by Jurkat T cells. The fungal metabolite, wortmannin, irreversibly inhibits PI3 kinase activity by binding to the 110-kDa PI3 kinase catalytic subunit (15) . Treatment of Jurkat cells with 0.1 ,uM wortmannin did not inhibit the induction of IL-2 production in response to combined stimulation with anti-CD28 mAb and PMA (Table 2 ). This concentration of wortmannin did inhibit specifically CD28-dependent P13 kinase activity in Jurkat T cells (data not shown). Treatment of Jurkat T cells with PMA and the anti-CD3 mAb OKT3 triggers signal transduction cascades that are distinct from those initiated by PMA and anti-CD28 mAb yet that also induce IL-2 production. PMA and anti-CD3 mAb-dependent stimulation of IL-2 production was not inhibited by nanomolar amounts of wortmannin. Treatment of cells with 10 ,uM wortmannin partially inhibited anti-CD3 mAbdependent stimulation of IL-2 production. At this high concentration, wortmannin can nonspecifically inhibit other lipid and protein kinases (11) . Nevertheless, this concentration of wortmannin did not inhibit anti-CD28-dependent induction of IL-2. Thus, selective inhibition of PI3 kinase activity with wortmannin did not inhibit IL-2 production after combined treatment of Jurkat T cells with PMA and anti-CD28 mAb.
DISCUSSION
Our studies demonstrate that treatment of Jurkat T cells with the protein kinase C-activating phorbol ester PMA leads to a striking inhibition of (i) the association of the 85-kDa subunit of P13 kinase with the cytoplasmic tail of CD28 (Fig. 3A) , (ii) the ability of p85 P13 kinase to be immunoprecipitated by anti-phosphotyrosine antibodies (Fig. 3 B-D) , and (iii) the induction of PI3 kinase activity (Fig. 2) after the stimulation of the cells with the anti-CD28 mAb 9.3. Importantly, these changes in PI3 kinase localization and activity occur using the same stimulation conditions that lead to CD28-dependent IL-2 production in Jurkat T cells. While treatment of Jurkat T cells with PMA at 5 ng/ml anti-CD28 mAb 9.3 at 1 ,ug/ml induced IL-2 production, there was no enhancement of P13 kinase Table 1 with anti-CD28 mAb 9.3 (1 ,ug/ml), anti-CD3 mAb OKT3 (5 ng/ml), PMA (5 ng/ml), and/or wortmannin as indicated. Cells were preincubated with wortmannin for 20 min prior to addition of other stimulatory agents. Wortmannin was added again after 6, 12, and 18 hr of culture. DMSO, dimethyl sulfoxide. activity using these stimulation conditions. The finding that wortmannin treatment did not inhibit CD28-dependent induction of IL-2 production further strengthens our conclusion that PI3 kinase is not required for CD28-dependent signaling leading to lymphokine production.
The cytoplasmic domain of CD28 is tyrosine phosphorylated after anti-CD28 mAb stimulation (2, 3) . The p85 subunit of P13 kinase then becomes physically associated with CD28, and there is rapid induction of PI3 kinase activity (Figs. 1-3 ) (3, (6) (7) (8) (9) (10) . Immunoprecipitation of P13 kinase by anti-phosphotyrosine antibody after CD28 stimulation was consistent with the activation-dependent tyrosine phosphorylation of either or both subunits of PI3 kinase (Fig. 3 B-D) .. In agreement with our studies, CD28-dependent tyrosine phosphorylation of the 110-kDa subunit of PI3 kinase has been observed (10, 16) , although the effect of tyrosine phosphorylation on PI3 kinase activity has not yet beeni determined.
We found, unexpectedly, that the same concentrations of PMA that synergize with anti-CD28 inAb for IL-2 production were inhibitory for the CD28-dependent induction of PI3 kinase activity (Fig. 2) . The inhibitory effect of PMA was rapid, persistent, and independent of the time of drug addition (Figs. 2B and 3 ) aiid of the incubation temperature ( Fig. 2A) .
The PMA-dependent inhibition was seen in both serumstarved (Fig. 2B ) and exponentially growing ( Fig. 2A ) Jurkat cells.
PMA treatment alone, in the absence of CD28 engagement, did not stimulate PI3 kinase activity as measured directly in NP-40 cell lysates or as immunoprecipitated with antibodies to either subunit of P13 kinase (data not shown). However, PMA had a dramatic effect on the physical association of PI3 kinase with CD28 (Fig. 3A) and on the CD28-dependent tyrosine phosphorylation of P13 kinase (Fig. 3 B-D) . We also found that treatment of Jurkat T cells with concentrations of wortmannin that inhibit PI3 kinase activity specifically had no effect on CD28-dependent IL-2 production (Table 2 ). Although PMA is not an in vivo component of intracellular signaling pathways, treatment of Jurkat T cells with PMA and anti-CD28 mAb leads to in cellullo production of IL-2. Thus, in our search for important early CD28-dependent signaling events, we have chosen a system with a well-defined and readily quantifiable functional outcome-namely, IL-2 production. An increased understanding of the molecular mechanisms by which a T cell can regulate the expression of this critical cytokine is important to understanding T-cell function.
Our data are consistent with a model in which PMA treatment of Jurkat T cells may prevent the association of P13 kinase with the cytoplasmic tail of CD28 and the accompanying stimulation of PI3 kinase activity. Physical association of P13 kinase with CD28 may also be required for the tyrosine phosphorylation of the kinase, which could affect its enzymatic activity. PMA activates protein kinase C (17) . Interestingly, the cytoplasmic domain of CD28 contains a consensus site for protein kinase C phosphorylation that is located near to the pYMNM site for p85 P13 kinase association. Phosphorylation of CD28 by PKC could alter the ability of p85 PI3 kinase (and/or other signaling proteins) to bind to CD28; we have recently found that PMA treatment increases the phosphorylation of CD28 on serine and threonine residues in vitro (J.E.H. and B.E.B., unpublished results). Changes in phosphorylation could also differentially affect the binding of the a and 13 isoforms of p85 P13 kinase. Isoform-specific differences have been reported in the phosphorylation of PI3 kinase after T-cell stimulation with phorbol esters (18) . While P13 kinase appears not to be necessary for lymphokine production, it may be
